NCT06129110 Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
| NCT ID | NCT06129110 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-01-31 |
| Primary Completion | 2028-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2024-01-31 with a primary completion date of 2028-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this intervention study is to learn about how weight loss impacts molecular signaling of intermuscular adipose tissue (IMAT) in individuals with obesity. The main question it aims to answer is how inflammatory molecules secreted by IMAT promote muscle insulin resistance and inflammation, and how these same molecules are diminished after weight loss. Following screening visits involving body composition measures, blood testing, strength testing, and a thigh muscle biopsy, participants will go through a 12-week dietary intervention for weight loss. After 12 weeks, this will be followed by the same testing and biopsies that were completed before the intervention. Researchers will then compare outcomes of individuals who lost weight to individuals who did not lose weight.
Eligibility Criteria
Inclusion Criteria: * Generally healthy men and women aged 18-70 * BMI between 30-40 * Less than 1 hour of exercise per week * Women: 1. may be pre or post menopausal Exclusion Criteria: * Type 1 or Type 2 diabetes * Thyroid disease * History of lung disease * Active use of nicotine * Severe plasma lipid disorders * Taking hormone replacement drugs, blood thinners, or thiazoladinediones * Women: 1. Currently going through menopause or peri-menopause 2. Pregnant or breastfeeding 3. History of Polycystic Ovary Syndrome
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06129110 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06129110 currently recruiting?
Yes, NCT06129110 is actively recruiting participants. Contact the research team at bryan.bergman@cuanschutz.edu for enrollment information.
Where is the NCT06129110 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT06129110 clinical trial?
NCT06129110 is sponsored by University of Colorado, Denver. The trial plans to enroll 70 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.